Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q8IXL6 (
RNS
)
1,091
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Calcium release through cardiac ryanodine receptors (
RyR2
) triggers heart muscle contraction. Reactive oxygen/nitrogen species (ROS/
RNS
), normally produced in the heart, promote endogenous
RyR2
S-nitrosylation and S-glutathionylation. These reversible redox modifications increase
RyR2
activity in vitro, and presumably also in vivo.
RyR2
S-glutathionylation increases under physiologically relevant conditions (tachycardia and exercise), suggesting that cardiac cells utilize this redox modification to increase
RyR2
activity under increased demand. In contrast, in vivo changes in
RyR2
S-nitrosylation in response to physiological stimuli remain uncharacterized. The number and identity of the highly reactive
RyR2
cysteine residues and the nature of the redox modification they undergo are presently unknown. Likewise, the physiological sources of ROS/
RNS
responsible for functionally relevant
RyR2
redox modifications have not been completely identified. The redox state of
RyR2
is altered in heart failure leading to enhanced
RyR2
activity, which presumably contributes to decrease SR calcium content and induce other calcium release abnormalities observed in heart failure. Greater understanding of
RyR2
redox modulation is necessary to counteract the deleterious consequences of
RyR2
activity deregulation caused by oxidative stress.
...
PMID:Modulation of cardiac ryanodine receptor activity by ROS and RNS. 2119 88